BACKGROUND: Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. METHODS: The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. RESULTS: There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. CONCLUSIONS: Polypills have the potential to lower CVD incidence substantially among US adults.
BACKGROUND: Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. METHODS: The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. RESULTS: There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. CONCLUSIONS: Polypills have the potential to lower CVD incidence substantially among US adults.
Authors: Bruce M Psaty; Thomas Lumley; Curt D Furberg; Gina Schellenbaum; Marco Pahor; Michael H Alderman; Noel S Weiss Journal: JAMA Date: 2003-05-21 Impact factor: 56.272
Authors: Kouta Ito; William H Shrank; Jerry Avorn; Amanda R Patrick; Troyen A Brennan; Elliot M Antman; Niteesh K Choudhry Journal: Health Serv Res Date: 2012-09-21 Impact factor: 3.402
Authors: Jennifer A Stewart Williams; Christopher J Wallick; Julie E Byles; Christopher M Doran Journal: Drugs Aging Date: 2013-03 Impact factor: 3.923
Authors: Márcio Sommer Bittencourt; Michael J Blaha; Ron Blankstein; Matthew Budoff; Jose D Vargas; Roger S Blumenthal; Arthur S Agatston; Khurram Nasir Journal: J Am Coll Cardiol Date: 2013-10-23 Impact factor: 24.094
Authors: Virginia Becerra; Alfredo Gracia; Kamal Desai; Seye Abogunrin; Sarah Brand; Ruth Chapman; Fernando García Alonso; Valentín Fuster; Ginés Sanz Journal: BMJ Open Date: 2015-05-09 Impact factor: 2.692
Authors: Matthew D Solomon; Ahalya Tirupsur; Evangelos Hytopoulos; Michael Beggs; Douglas S Harrington; Cynthia French; Thomas Quertermous Journal: Clin Cardiol Date: 2013-08-08 Impact factor: 2.882
Authors: James D Pollard; Kazi T Haq; Katherine J Lutz; Nichole M Rogovoy; Kevin A Paternostro; Elsayed Z Soliman; Joseph Maher; Joo A C Lima; Solomon K Musani; Larisa G Tereshchenko Journal: Eur Heart J Digit Health Date: 2021-01-20